Last updated 12 March 2019
We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
GSK is experiencing supply constraints of the below hepatitis-containing vaccines. These supply constraints are due to manufacturing capacity and are not related to vaccine quality or safety.
- Havrix Junior - inactivated hepatitis A virus vaccine
- Twinrix Adult - combined hepatitis A and hepatitis B vaccine
- Twinrix Junior - combined hepatitis A and hepatitis B vaccine (from April 2019)
Supply of GSK’s hepatitis-containing vaccines to Government programs are not impacted.
Please note, the following GSK hepatitis containing vaccines continue to be in stock.
- Engerix B Adult - hepatitis B surface antigen recombinant (yeast) vaccine
- Engerix B Paediatric hepatitis B surface antigen recombinant (yeast) vaccine
- Havrix Adult - inactivated hepatitis A virus vaccine
We expect to provide the next update in July 2019.
GSK is experiencing a supply constraint of its rabies vaccine, Rabipur (inactivated rabies virus vaccine). This supply constraint is due to operational factors and is not related to vaccine quality or safety.
This shortage impacts those who wish to purchase Rabipur for pre-exposure vaccination. For example; those travelling to high rabies risk countries.
GSK understands that all State and Territory Health Departments stockpile rabies vaccines (including Rabipur) for post-exposure prophylaxis (for those individuals who have received an animal wound and considered to be at risk of rabies). We are working with the States and Territories who stock Rabipur to maintain emergency post-exposure stockpiles.
Anyone who needs access to a rabies vaccine should contact their healthcare professional.
Measles, mumps, rubella & varricella (MMRV) combination vaccine
GSK is anticipating a supply constraint of its measles, mumps, rubella & varicella (MMRV) combination vaccine, Priorix Tetra from the end of April to end October 2019.
This shortage will impact our ability to supply vaccines to the National Immunisation Program (NIP). GSK has worked with the Department of Health to ensure that an alternative MMRV vaccine will be available during this time, ensuring no impact to children’s immunisations through the NIP.
We expect a small number of doses to be available to the private market until June 2019.
Herpes zoster vaccine
GSK’s herpes zoster vaccine, Shingrix, is not available in Australia. There is currently no confirmed timing for the supply of Shingrix to Australia.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.